Peter Schmid, PHD Dr

Trials

Studies that name Peter Schmid, PHD Dr as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:38 UTC. Open this list on ClinicalTrials.gov

• Ph3
  NCT07281833 · Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment

  Women's Cancer Study Group GmbH · recruiting · Breast Cancer, HR-positive Breast Cancer, Advanced Breast Cancer · principal investigator
• Ph3
  NCT07242352 · Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC

  Women's Cancer Study Group GmbH · recruiting · Breast Cancer, HR+/HER2- Breast Cancer · principal investigator
• Ph3
  NCT07178730 · NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

  Women's Cancer Study Group GmbH · not yet recruiting · Breast Cancer, Triple-negative Breast Cancer · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 12:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 37 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.